Montreal-based company, The Good Shroom (TSTX:MUSH), announced its financial results for the quarter ended on April 30, 2024. The report includes results for the subsidiary Teonan Biomedical Inc.
"The consistent profitability this quarter, despite a challenging market, highlights our focused execution and strategic adaptations," stated Eric Ronsse, CEO. This quarter marks the company's fifth consecutive profitable quarter, emphasizing its resilience and operational efficiency.
Year-Over-Year Financial Highlights:
- Gross Revenue: The company reported a slight decrease in quarterly sales, amounting to $1,135,991 compared to $1,266,186 in the same quarter last year. This marks a decrease of approximately 10.3%
- Net Profit: There was an improvement in net profitability. Net profits rose to $30,840 from $13,660 the previous year, reflecting an effective cost-cutting strategy.
"The slight drop-off in sales can be explained by less overall demand resulting from price competition and increased product assortment" reads the Management Discussion & Analysis report.
Operational Highlights:
- Cannabis products accounted for 96% of revenue and the company continues to lead with innovation, notably in its development of THC-infused pouches. This product is aimed at offering a competitive edge in the market. It also leverages a popular consumption method akin to nicotine pouches, but with THC. This Innovation could position The Good Shroom Co. as a pioneer in this segment.
- The emphasis on strategic growth is reflected in the decision to expand beyond Quebec, where 90% of their sales for the quarter happened.
- The Good Shroom owes no outstanding excise taxes or debt, which is an outstanding issue for other companies in Canada.
Read also: Tax Debt Crisis: Struggling Cannabis Producers In Canada Pushed To Breaking Point
Stock Options For Board Members
On June 20, 2024, The Good Shroom Co issued stock options to each board member and the CFO. Stocks totaled 100,000, with an exercise price set at $0.11 per share. Value corresponds to the closing price of stocks on the TSX Venture Exchange as of June 19, 2024. These options are set to expire on June 19, 2032.
总部位于蒙特利尔的公司The Good Shroom（TSTX: MUSH）公布了截至2024年4月30日的季度财务业绩。该报告包括子公司Teonan Biomedical Inc的业绩。
首席执行官埃里克·龙斯表示：“尽管市场充满挑战，但本季度持续的盈利能力凸显了我们专注的执行和战略调整。”本季度是该公司连续第五个季度盈利，凸显了其弹性和运营效率。
同比财务亮点：
- 总收入：该公司报告季度销售额略有下降，为1,135,991美元，而去年同期为1,266,186美元。这标志着下降了大约 10.3%
- 净利润：净盈利能力有所改善。净利润从去年的13,660美元增至30,840美元，这反映了有效的削减成本战略。
管理层讨论与分析报告写道：“销售额略有下降可以用价格竞争和产品种类增加导致整体需求减少来解释。”
运营亮点：
- 大麻产品占收入的96％，该公司继续在创新方面处于领先地位，特别是在开发注入四氢大麻酚的袋子方面。该产品旨在提供市场竞争优势。它还利用了一种流行的消费方式，类似于尼古丁袋，但含有四氢大麻酚。这项创新可能会使The Good Shroom Co. 成为该领域的先驱。
- 将业务扩展到魁北克以外的地区这一决定反映了对战略增长的重视，他们本季度90％的销售额来自魁北克。
- Good Shroom没有未缴的消费税或债务，这对加拿大其他公司来说是一个悬而未决的问题。
另请阅读：税收债务危机：加拿大陷入困境的大麻生产商已走向临界点
董事会成员的股票期权
2024年6月20日，The Good Shroom Co向每位董事会成员和首席财务官发行了股票期权。股票总额为10万股，行使价定为每股0.11美元。价值对应于截至2024年6月19日多伦多证券交易所风险交易所股票的收盘价。这些期权定于2032年6月19日到期。
